Please assess the completion status of the following clinical trial:

Trial Title: Quantifying Airway Inflammation With Radiologic Tests

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: EARLY_PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy, man or woman, any race or ethnicity, age 19 - 44 years old~* Screening FEV1 and FVC must be \> 80% of predicted.~* Screening oxygen saturation by pulse oximetry is \>97% on room air.~* Research volunteer must be capable of lying still and supine within the PET scanner for \~2 ½ hours.~* Research volunteer must be capable of fasting for 6 hours.~Exclusion Criteria:~* Pregnancy (confirmed by a qualitative urine hCG pregnancy test)~* Lactation.~* Actively menstruating at time of randomization~* History of tobacco use or has smoked other illicit drugs (marijuana, cocaine) in the past year.~* Research volunteer is currently taking any prescription medications.~* Research volunteer is at increased risk for radiation exposure (e.g. flight attendants)~* Research volunteer is enrolled in another research study of an investigational drug.~* Research volunteer has a known allergy to both trimethoprim/sulfamethoxazole and amoxicillin.~* Research volunteer has a known allergy to drugs routinely used during bronchoscopy.~* Research volunteer has a known allergy to lovastatin or rhAPC~* Fasting glucose at time of PET study \> 150 mg/dl.~* Exclusion criteria related to use of rhAPC:~  * Active or history of internal bleeding within the past 3 months~ * History of hemorrhagic stroke within the past 3 months.~ * History of intracranial or intraspinal surgery, or severe head trauma, within the past 3 months~ * History of trauma with an increased risk of life-threatening bleeding within the past 3 months~ * History of receiving thrombolytic therapy within the past 3 months.~ * History of receiving oral anticoagulants or glycoprotein IIb/IIIa inhibitors within the past 3 months.~ * History of using aspirin \> 650 mg/d or other platelet inhibitors within the past 7 days.~ * Any history of intracranial arteriovenous malformation or aneurysm~ * Any history of a known bleeding diathesis~ * Any history of chronic severe hepatic disease~ * Presence of an epidural catheter~ * Any history of intracranial neoplasm or mass lesion or evidence of cerebral herniation~ * Use of heparin during past 7 days~ * Platelet count \<100,000 x 106/L~ * Prothrombin time-INR \> 1.5~ * SGOT \>47 IU/L, SGPT \> 53 IU/L, or bilirubin \> 1.1 mg/dl~ * Any other condition in which bleeding constitutes a significant hazard or would be particularly difficult to manage because of its location.~* Exclusion criteria related to use of lovastatin:~  * History of chronic active liver disease or acute liver disease within the past 3 months~ * SGOT \>47 IU/L, SGPT \> 53 IU/L, or bilirubin \> 1.1 mg/dl.

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 44 Years
- Healthy Volunteers: t

Study Arms:
- Placebo pill and placebo IV (Type: PLACEBO_COMPARATOR): None
- Lovastatin pill and placebo IV (Type: EXPERIMENTAL): None
- Placebo pill and rhAPC IV (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).